Abstract: Background: Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (mRCC). In this study, our objective was to evaluate the effectiveness of sunitinib or pazopanib in patients with intermediate or poor risk metastatic renal cell carcinoma. Methods: A total of 60 patients with metastatic renal cell carcinoma were retrospectively evaluated between January 2014 and December 2020. Survival analyzes were performed with the Kaplan-Meier and log-rank tests. Results: Forty-six (76.7%) patients were male. Of the patients who received sunitinib, 22 patients (57.9%) were in the intermediate risk group, while 16 patients (42.1%) were in the poor risk group. Among patients receiving pazopanib, 14 patients (63.6%) were in the intermediate-risk group, while 8 patients (36.4%) were in the poor-risk group. There were no significant difference in the intermediate risk group of patients in terms of median progression-free survival between sunitinib and pazopanib (p=0.742). No significant differences were found in terms of progression-free survival in the high-risk group of patients (p=0.254). There were no significant differences in overall survival in the intermediate-risk group of patients receiving sunitinib or pazopanib (p = 0.377). There were no significant differences in terms of overall survival in the high-risk patient group receiving sunitinib or pazopanib (p = 0.3777). Conclusions: There were no significant difference in terms of progression-free survival and overall survival between the intermediate and poor-risk patient groups receiving pazopanib or sunitinib.Abstract: Background: Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (mRCC). In this study, our objective was to evaluate the effectiveness of sunitinib or pazopanib in patients with intermediate or poor risk metastatic renal cell carcinoma. Methods: A total of 60 patients with met...Show More
Abstract: The dialectical contradictions constitute the driving force for the development of the training activity, in particular for the training of Oncological Surgery. The previous idea reveals the negative result of malnutrition in cancer patients and its association with high rates of postoperative morbidity and mortality; therefore, the scientific divergences related to the nutritional support of the malnourished oncological patient leads to an individualized approach during the clinical-surgical follow-up of these complex cases. In addition to the establishment of guidelines that identify the type of tumor and evolutionary stage based on the development of nutrition in recent years and the advances derived from the epistemological deepening of immunology, molecular biology and other sciences. The objective of this study was to consider the importance of the categorical relationship between nutrition and surgery in cancer patients to improve the nutritional approach of these patients in clinical-surgical practice and training dynamics. Finally, the identification of the categorical binomial surgery and nutrition is unavoidable in the surgical treatment of cancer patients because it allows recognizing the negative impact on the health of these patients by revealing the high possibility of complications and death. Likewise, the relationship between the nutritional situation prior to the intervention and the subsequent evolution of the cancer patient.Abstract: The dialectical contradictions constitute the driving force for the development of the training activity, in particular for the training of Oncological Surgery. The previous idea reveals the negative result of malnutrition in cancer patients and its association with high rates of postoperative morbidity and mortality; therefore, the scientific dive...Show More
